(0.26%) 5 145.00 points
(0.16%) 38 502 points
(0.40%) 17 917 points
(-0.62%) $83.33
(1.82%) $1.958
(-0.12%) $2 344.30
(-0.04%) $27.52
(2.86%) $948.50
(-0.01%) $0.935
(-0.06%) $11.02
(-0.23%) $0.799
(1.89%) $93.61
@ $6.80
发出时间: 15 Feb 2024 @ 03:06
回报率: -45.44%
上一信号: Feb 14 - 22:30
上一信号:
回报率: 2.45 %
Live Chart Being Loaded With Signals
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally...
Stats | |
---|---|
今日成交量 | 1.04M |
平均成交量 | 1.63M |
市值 | 335.07M |
EPS | $0 ( 2024-03-14 ) |
下一个收益日期 | ( $-0.390 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.69 |
ATR14 | $0.00400 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-20 | O'byrne Jason | Buy | 153 000 | Option to purchase Common Stock |
2024-02-20 | O'byrne Jason | Buy | 33 000 | Common Stock |
2024-02-20 | Mcclung Barbara G | Buy | 33 000 | Common Stock |
2024-02-20 | Mcclung Barbara G | Buy | 153 000 | Option to purchase Common Stock |
2024-02-20 | Khan Ruhi Ahmad | Buy | 153 000 | Option to purchase Common Stock |
INSIDER POWER |
---|
93.28 |
Last 96 transactions |
Buy: 4 096 718 | Sell: 409 985 |
音量 相关性
Caribou Biosciences, Inc. 相关性 - 货币/商品
Caribou Biosciences, Inc. 财务报表
Annual | 2023 |
营收: | $34.48M |
毛利润: | $30.95M (89.78 %) |
EPS: | $-1.380 |
FY | 2023 |
营收: | $34.48M |
毛利润: | $30.95M (89.78 %) |
EPS: | $-1.380 |
FY | 2022 |
营收: | $13.85M |
毛利润: | $10.21M (73.71 %) |
EPS: | $-1.640 |
FY | 2021 |
营收: | $9.60M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.95 |
Financial Reports:
No articles found.
Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。